Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial performance, with a 25% revenue increase and a shift to net income, indicating effective management. Despite higher R&D expenses, the positive revenue growth and net income are promising. The lack of strategic updates or risk discussions in the call is offset by the strong financial results. With no negative sentiment from the Q&A, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.
Key Financial Performance
Revenue Legend Biotech reported revenue of $120 million for Q1 2026, representing a 25% increase year-over-year. This growth was primarily driven by strong sales of CARVYKTI® and expanded market penetration.
Net Income The company achieved a net income of $15 million, compared to a net loss of $5 million in Q1 2025. This improvement was attributed to increased revenue and effective cost management.
Research and Development Expenses R&D expenses were $45 million, up 12% year-over-year, due to ongoing investments in pipeline development and clinical trials.
Operating Expenses Operating expenses totaled $60 million, reflecting a 10% increase from the previous year, driven by higher R&D spending and marketing efforts for CARVYKTI®.
Cash and Cash Equivalents The company reported $500 million in cash and cash equivalents, a 5% decrease from the previous year, primarily due to increased investments in R&D and infrastructure.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alan Bash
Biliouris Oppenheimer
Biotech Conference
CARVYKTI Carlos
Carlos Santos
Chase Co
Co Research
Conference Instructions
Development Terence
Director Alan
Division Ashwani
Division EDT
Division Eric
Division Etzer
Division Fye
Division Konstantinos
Division Leonid
Division Sean
Division Umer
Division Yaron
EDT day
Eric Schmidt
Etzer Darout
Finance
Fye JPMorgan
Inc Research
Instructions Today
JPMorgan Chase
Konstantinos Biliouris
Legend Biotech
Leonid Timashev
McCutcheon
Research Division
Vice President
LEGN Transcript
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary highlights strong financial performance, with a 25% revenue increase and a shift to net income, indicating effective management. Despite higher R&D expenses, the positive revenue growth and net income are promising. The lack of strategic updates or risk discussions in the call is offset by the strong financial results. With no negative sentiment from the Q&A, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call and Q&A reveal a positive outlook with plans for CARVYKTI expansion, strong market penetration, and strategic partnerships. The company projects profitability by 2026 and is addressing hurdles for community expansion. Analysts' questions indicate confidence in growth, and management's responses highlight significant opportunities, especially in the U.S. and ex-U.S. markets. Despite some uncertainties, the overall sentiment is optimistic, supported by strategic initiatives and market validation of CAR-T therapy.
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call highlights operational breakeven for CARVYKTI and company-wide profitability by 2026, which are positive indicators. The removal of REMS by the FDA, expansion plans, and strong demand in international markets further support a positive outlook. However, management's reluctance to provide specific timelines and details in some areas tempers expectations. Overall, the strategic plan and Q&A insights suggest a positive sentiment, likely resulting in a stock price increase of 2% to 8%.
LEGN Slides
LEGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
